About Enara Bio
Enara Bio is a company based in Oxford (United Kingdom) founded in 2016.. Enara Bio has raised $84.05 million across 5 funding rounds from investors including RA Capital, The Francis Crick Institute and Pfizer Ventures. The company has 38 employees as of December 31, 2021. Enara Bio offers products and services including EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies. Enara Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Oxford, United Kingdom
- Employees 38 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Enara Bio Limited
- Date of Incorporation 08 Nov, 2016
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
$5.89 M (USD)-14as on Dec 31, 2022
-
Net Profit
$-13.33 M (USD)-27as on Dec 31, 2022
-
EBITDA
$-17.24 M (USD)-21as on Dec 31, 2022
-
Total Equity Funding
$84.05 M (USD)
in 5 rounds
-
Latest Funding Round
$32.5 M (USD), Series B
Oct 03, 2024
-
Investors
RA Capital
& 5 more
-
Employee Count
38
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enara Bio
Enara Bio offers a comprehensive portfolio of products and services, including EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for discovering cancer-specific Dark Antigens.
Novel antigens used in developing immunotherapies.
Treatments targeting cancer through T-cell biology.
Unlock access to complete
Unlock access to complete
Funding Insights of Enara Bio
Enara Bio has successfully raised a total of $84.05M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $32.5 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $32.5M
-
First Round
First Round
(18 Dec 2017)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series B - Enara Bio | Valuation | M Ventures , Pfizer Ventures | |
| May, 2021 | Amount | Series A - Enara Bio | Valuation |
investors |
|
| Nov, 2019 | Amount | Series A - Enara Bio | Valuation | SV Health Investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Enara Bio
Enara Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, The Francis Crick Institute and Pfizer Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed by Pfizer-backed firm since 2004.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Enara Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Enara Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Enara Bio Comparisons
Competitors of Enara Bio
Enara Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Enara Bio
Frequently Asked Questions about Enara Bio
When was Enara Bio founded?
Enara Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Enara Bio located?
Enara Bio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of Enara Bio?
Kevin Pojasek is the current CEO of Enara Bio.
Is Enara Bio a funded company?
Enara Bio is a funded company, having raised a total of $84.05M across 5 funding rounds to date. The company's 1st funding round was a Series A of $17.5M, raised on Dec 18, 2017.
How many employees does Enara Bio have?
As of Dec 31, 2021, the latest employee count at Enara Bio is 38.
What is the annual revenue of Enara Bio?
Annual revenue of Enara Bio is $5.89M as on Dec 31, 2022.
What does Enara Bio do?
Enara Bio was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector focused on cancer immunotherapy. Operations center on identifying and characterizing targets such as dark antigens from genomic dark matter and those presented by the cancer-specific MR1 receptor. Proprietary TCR-directed T-cell therapies are offered to address tumor heterogeneity, alongside cancer vaccines for polyclonal autologous ex vivo T-cell stimulation.
Who are the top competitors of Enara Bio?
Enara Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Enara Bio offer?
Enara Bio offers EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies.
Who are Enara Bio's investors?
Enara Bio has 6 investors. Key investors include RA Capital, The Francis Crick Institute, Pfizer Ventures, M-Ventures, and Samsara BioCapital.
What is Enara Bio's valuation?
The valuation of Enara Bio is $61.61M as of May 2021.